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Medicaid Risk-Adjustment Model with Diagnosis and Pharmacy-Based Adjusters:
Does It Work?
Yanen Li
ABSTRACT
National health expenditures will continue to grow faster than nominal gross
domestic product (GDP) in the early 21st century (Heffler et al., 2002; Heffler et al.,
2005). Increased Medicaid costs have spurred research to find reliable cost-saving
methodologies (Kronick et al., 1996). The Medicaid administrations of some states
have chosen risk adjustment as a methodology for savings (Tollen et al., 1998;
Weiner et al., 1998), since it can reduce the financial burden of health care providers
and distribute medical resources more efficiently. This dissertation presents a riskadjustment model based on two types of health condition adjusters: diagnosis-based
HCC adjusters and pharmacy-based RxRisk adjusters. HCC adjusters were developed
from different diagnostic categories from inpatient, outpatient and long-term care
data. RxRisk adjusters included diseases inferable from prescription drug usage. The
underlying assumption is that using both types of health condition adjusters, rather
than relying on either diagnosis-based adjusters or pharmacy-based adjusters alone
can help increase predictive power and lower Medicaid’s risk of reimbursing inflated
medical costs for its beneficiaries. The population in this study consisted of all
disabled and aged Florida adults who were eligible for Florida’s Medicaid program in
state fiscal year (SFY) 2002-03 and state fiscal year 2003-04. The population was
broken down into two subpopulations: disabled Medicaid beneficiaries aged 64 and
under and beneficiaries aged 65 or over.
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The proposed regression model includes diagnostic and pharmacy-based
adjusters, and this dissertation compares the proposed model with models based
solely on pharmacy- or diagnosis-based adjusters.
The results presented in this dissertation demonstrate the proposed model
has higher predictive power than the diagnosis-based HCC model and the pharmacybased RxRisk model for the overall population and the subpopulations in this study.
Risk-adjustment models using diagnostic and prescription drug information have
higher predictive power and decrease the possibility of inappropriate gaming of the
Medicaid capitation payment system.

v

Chapter One
Introduction
National health expenditures continue to grow faster than nominal gross
domestic product (GDP). Some researchers (Heffler et al., 2002) have projected that
national health expenditures will be $2,815.8 billion in 2011 and will constitute
approximately 17 percent of GDP. This compares with 13.2 percent in 2000. Heffler
and colleagues (2005) also predicted that national health expenditures would
comprise 18.7 percent of the GDP in 2014.
Health spending can be divided into two categories: the public and private
sectors (Levit et al., 2003). Public-sector health spending includes Medicare and
Medicaid expenditures. Medicare is a federal program that pays for hospitalization,
physician services, short-term nursing home care, and outpatient care expenses for
the aged. It also pays for medical care for the permanently disabled. In the past
century, Medicare could not cover outpatient prescription drug costs. However,
Medicare beneficiaries began receiving Medicare drug benefits under the Medicare
Part D program on January 1, 2006. Medicaid is funded by the federal and state
governments and provides health care and health-related services to eligible lowincome individuals and people with disabilities. Private health insurance and out-ofpocket expenditures constitute the private sector of national health spending. The
growth of private spending was expected to slow down sharply in 2006 when the
Medicare drug benefit plan was introduced. However, the growth of public-sector
health expenditures could accelerate because Medicare started covering some
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prescription drug costs which were paid by beneficiaries prior to the introduction of
the Medicare Part D program (Heffler et al., 2005).
The growth of Medicaid expenditures may also accelerate for another reason;
a slowdown in the economy may lead to more Medicaid enrollees, since Medicaid
serves low-income individuals (Weil, 2003). Other factors associated with higher
Medicaid costs include increased health care costs and costs associated with
advanced medical technology. Medicare costs are less influenced by the economy
since all people aged 65 or older are eligible for Medicare.
The acceleration of Medicaid spending has encouraged research into costcontainment methods. Some methods emphasize the control of prescription drug
costs: drug formulary, a price ceiling on drugs, prescription-renewal limitations,
dollar limits per prescription, and co-payment plans (Moore and Newman, 1993).
Drug formularies are lists of drugs reimbursable for certain diagnoses. State Medicaid
offices can establish “pharmacy and therapeutics committees” to evaluate drug
formularies. The pharmacy and therapeutics committee approves drugs for Medicaid
reimbursement. Moore and Newman (1993) evaluated the drug formulary
methodology and suggested the restriction of prescription drug usage may yield a
lower level of health benefits and fail to lower medical costs significantly. Lower drug
usage may be associated with a surge in alternative therapy use, eventually
increasing total health care costs. Since prescription drug costs are part of total
medical expenditures, including physician and inpatient services, simply controlling
prescription drug benefit alone may inadvertently result in limited and incomplete
cost savings (Dranove, 1989; Moore and Newman, 1993).
Another cost-containment strategy is reducing payment rates for some
physician and outpatient services. This strategy may shift the financial burden to
health care providers and lower medical costs inefficiently.
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Increased Medicaid costs have stimulated health care researchers and
policymakers to find more feasible and reliable cost-saving methodologies. The
Medicaid administrators of many states have chosen risk adjustment because it can
reduce the financial burden on health care providers and distribute medical resources
more efficiently. Risk-adjustment strategies use the health status of patients to
predict future medical costs. Researchers review diagnoses or prescription drug
usage to infer health status of beneficiaries and build risk-adjustment models based
on inferred health status and other variables. Such models have been reported to
have higher predictive power than models based solely on demographic factors such
as age, gender, and geographic location for projecting medical expenditures (Ellis et
al., 1996; Pope et al., 2000; Riley, 2000). Health plans tend to enroll healthier
patients under capitation systems based on demographic factors, which provides
them with greater profit margins, since predicted costs for healthier and sicker
patients are equal under demographic models. Risk-adjustment models can more
equitably reimburse health plans having a large proportion of sick enrollees and
decrease incentives to enroll the healthiest enrollees (Ash et al., 2000; Ettner et al.,
2000; Pope et al., 2000).
Some risk-adjustment models may establish perverse incentives (Fishman et
al., 2003; Gilmer et al., 2001; Pope et al., 2000). For example, models based on
primary inpatient diagnosis encourage more hospitalization (Pope et al., 2000).
Outpatient services that tend to be less expensive than corresponding inpatient
services might in some cases be inadvertently replaced with inpatient services, and
models based on prescriptions have been shown to actually increase prescription
drug usage (Fishman et al., 2003; Gilmer et al., 2001).
State Medicaid offices have been actively seeking a capitation payment
system based on a risk-adjustment model having high predictive power and low
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potential for gaming. This dissertation presents a model based on multiple types of
health status predictors, which are assumed to increase predictive power and lower
the risk of gaming by providers.
Study Rationale
In the past two decades, researchers have tried to establish a risk-adjustment
model with a high predictive capacity for both Medicare and Medicaid capitation
payment systems. Models have been built on diagnoses (Ash et al., 2000; Ellis et al.,
1996; Fishman et al., 2003; Kronick et al., 2000; McCall and Korb, 1998; Pope et
al., 2000) and on prescription drug usage (Fishman et al., 2003; Meenan et al.,
2003; Sales et al., 2003; Sloan et al., 2003). Both models have advantages and
disadvantages, and these are discussed in the literature review section. The purpose
of this dissertation is to build a new predictive model for the Florida Medicaid
capitation payment system that draws on both diagnoses and prescription drug
usage from patient claims files.
Review of the Literature
Many studies have been undertaken to examine risk-adjustment
methodologies for the Medicare capitation payment system. Although the goal of this
dissertation is to build a new risk-adjustment model for the Medicaid capitation
payment system, the literature on risk adjustment for Medicare capitation payment
is reviewed since Medicare and Medicaid cover similar medical costs of their
beneficiaries.
Starting in the 1980s, Medicare beneficiaries could choose managed care
plans as an alternative to the fee-for-service option. The Health Care Financing
Administration (HCFA) compensates managed care organizations by a predetermined
payment amount for each Medicare health maintenance organization (HMO) enrollee,
according to capitation rates set in advance. Before risk-adjustment models, the
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adjusted average per capita cost (AAPCC) model was launched in 1985. The
capitation payment of the AAPCC model is calculated by the formula: Payment =
(0.95)* (County Per Capita Costs/Average County Demographic Score)*Enrollee
Demographic Score. Under the AAPCC model, health plans are reimbursed according
to a predetermined amount predicted by Medicaid beneficiaries’ demographic
characteristics only (age, gender, welfare status, and institutional status); the health
status of Medicare beneficiaries is not used as a predictor in this model. Some
researchers reported that Medicare HMOs could cherry-pick healthier beneficiaries
from the Medicare population (Brown, 1988; Brown et al., 1993; Hill & Brown, 1990;
Lichtenstein et al., 1991; Mello et al., 2003; Morgan et al., 1997) since sicker
beneficiaries may have higher medical costs than predicted based on demographic
models. Medicare HMO beneficiaries also have lower mortality rates than Medicare
fee-for-service (FFS) beneficiaries (Brown, 1988; Brown and Langwell, 1988). The
AAPCC model explained only 1 percent of the variance in total annual medical
expenditures of Medicare beneficiaries (Ash et al., 1989; Ellis et al., 1996;
Newhouse, 1986). Some researchers suggest an ideal risk-adjustment model could
predict 20 to 25 percent of the variance in medical costs (Newhouse et al., 1989).
Since the AAPCC model has much lower predictive power than an ideal model, it
does not have enough capacity to predict medical costs accurately. Predicted medical
costs can be significantly higher than actual medical costs for healthier patients and
lower for sicker patients.
Several researchers discuss models based on other risk adjusters; selfreported health status (Fowles et al., 1996; Hornbrook and Goodman, 1996),
perceived health status (Epstein and Cumella, 1988; Gruenberg et al., 1996;
Hornbrook and Goodman, 1996) or functional status (Epstein and Cumella, 1988;
Hornbrook and Goodman, 1996; Lichtenstein and Thomas, 1987) has been used to
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build risk-adjustment models. However, some researchers argue that it is timeconsuming and costly to collect self-report data (Pacala et al., 2003).
Compared to self-reported health and functional status, diagnoses in claims
files have advantages as medical cost predictors: (1) they are easy to obtain from
hospital records or physicians’ offices; (2) they are made by physicians, and hence
more objective than self-reported predictors; (3) the collection costs are lower since
diagnoses are extant in hospitalization and outpatient files. Comparisons of model
performance have yielded varying results: some researchers report diagnosis-based
models have higher predictive power than models based on self-reported health
status (Fowles et al., 1997) while opposite results were reported by Pacala and
colleagues (2003). Generally, when diagnoses are available, researchers recommend
using diagnosis-based models (Fowles et al., 1997; Hornbrook and Goodman, 1996).
A new Medicare capitation payment system as well as health status risk
adjusters were mandated under the Balanced Budget Act of 1997; and the new
system went into effect in 2000. Since diagnosis-based models have higher
performance, the Health Care Financing Administration (HCFA) incorporates
diagnostic information into the Medicare capitation payment system, and has funded
studies on different risk-adjustment methods based on diagnostic information. These
methods include the Principal Inpatients Diagnostic Cost Group (PIPDCG) model
based solely on inpatient data, the multi-condition Hierarchical Condition Category
(HCC) model based on inpatient and outpatient diagnoses, and the pharmacy-based
RxRisk model.
The demographic AAPCC model was initially incorporated into the Medicare
capitation payment system. Since the AAPCC model lacks predictive power (Ash et
al., 1989; Newhouse, 1986; Pope et al., 2000) and the ability to prevent health
plans gaming the Medicare capitation payment system (Brown et al., 1986; 1988;
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1993; Brown and Langwell, 1987; Eggers and Prihoda, 1982; Lubitz and Prihoda,
1984; Beebe, Lubitz, and Eggers, 1985), Congress passed the Balanced Budget Act
of 1997 and requested the HCFA to replace the AAPCC model with a risk-adjustment
model before January 1, 2000. The PIPDCG model was chosen to be part of the
Medicare capitated payment system in 2000. The PIPDCG model was developed by
researchers at Boston University, Brandeis University, Harvard University, and Health
Economics Research, Inc. and it was selected because it could be developed in a
short time frame. As a model based solely on inpatient data, the PIPDCG model is
more feasible than other models because hospitalization data are easily obtained
from health plans and health care providers, and hospitalization data are associated
with the severity of clinical diseases and symptoms (Pope et al., 2000). Data of short
hospital stay (less or equal to one day) are excluded from the PIPDCG model
because Medicare beneficiaries can be inappropriately hospitalized for higher
Medicare reimbursement by health plans.
Demographic variables of the PIPDCG model are similar to the variables of the
AAPCC model (Pope et al., 2000). In the AAPCC model, demographic adjusters are:
age, gender, welfare status, and institutional status. Beneficiaries are divided into 20
categories, 10 for men and the other 10 for women. In the PIPDCG model, the only
change is that the “age 85 or over” group in the AAPCC model was removed and the
“age 85-89,” “age 90-94,” and “age 95 or over” categories were added to the
PIPDCG model. There are 24 age-gender categories in the PIPDCG model. Medicaid
status is included in the PIPDCG model, and institutional status is removed because
it was found to have no significant effect on annual medical expenditures in the
PIPDCG model (Pope et al., 2000).
The “Originally disabled” variable is another demographic adjuster introduced
in the PIPDCG model. Disabled Medicare beneficiaries can be enrolled in the Medicare
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program when they are younger than 65 years old under specific conditions. Their
medical costs are significantly higher than other beneficiaries, and an “originally
disabled” adjuster may predict an increase in medical costs after controlling for other
variables (Pope et al., 2000). Working-age status is another demographic adjuster
used in the PIPDCG model, and it refers to Medicare beneficiaries who are employed
and offered private insurance when they receive Medicare benefits. When Medicare
beneficiaries qualify for “working-age” status, 21 percent of their medical costs are
paid by Medicare.
Researchers (Ash et al., 1989; Ellis and Ash, 1995; Ellis et al., 1996; Pope et
al., 2000) developed the PIPDCG model by using the primary diagnosis in
hospitalization data and categorizing diagnoses into certain diagnostic cost groups
(DCGs). Since diagnoses in hospitalization data were coded according to the
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9CM), the DCGs are built on 14,000 ICD-9-CM codes (Ash et al., 1989; Ellis and Ash,
1995). Ellis and Ash (1996) classified 104 groups of diagnoses into 143 principal
inpatient DXGROUPs, and these principal inpatient DXGROUPs were regrouped into
25 PIPDCG categories. Pope and colleagues (2000) made refinements by
categorizing the ICD-9-CM codes (more than 15,000) into 172 Principal Inpatient
Diagnostic Groups (PIPDxGs), and created 26 PIPDCG categories. A new PIPDCG
category added was PIPDCG 4, which is “no or excluded inpatients admissions,
ectopic pregnancy, miscarriage/terminated pregnancy, completed pregnancy with
major complications, completed pregnancy with complications, completed pregnancy
without complications (normal delivery)”. Each PIPDCG category represented a group
of diseases that were clinically related and required similar payments. Rare diseases
were excluded when researchers developed them from a five-percent sample of
Medicare’s FFS enrollees. Ranks of PIPDCG categories were positively associated with
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medical costs after adjustment of demographic predictors. For example, PIPDCG 29,
which is the “HIV/AIDS, bloods, lymphatic cancer/neoplasms” category, is the
reference patient group with the highest average medical expenditures ($30,456) in
1996 (Pope et al., 2000). PIPDCG 4 was referred to as the group of people who were
not hospitalized or who were hospitalized without significant increases in medical
expenditures after adjusting for demographics.
The PIPDCG model included demographic and 16 PIPDCG variables (Pope et
al., 2000). As a prospective risk-adjustment model, the PIPDCG model has more
predictive power than the AAPCC model (Ellis et al., 1996; Pope et al., 2000). Ellis
and colleagues (1996) report that the R2 value of the PIPDCG model was 5.5
percent, and Pope and colleagues (2000) report an R2 value of 6.2 percent,
compared with the lower value of the AAPCC model (1 percent). Consistent results
can be found in other studies (McCall and Korb, 1998; Robinson and Karon, 2000;
Temkin-Greener, 2001). Since Pope and colleagues (2000) re-code the PIPDXGs and
make some refinements to the PIPDCG model, 6.2 percent may be closer to the
predictive power of this model. Moreover, Pope and colleagues (2000) use a fivepercent sample of Medicare’s FFS enrollees in 1995 and 1996, consistent with the
1991 and 1992 sample (Ellis et al., 1996) used to establish the PIPDCG model. Other
studies (McCall and Korb, 1998; Robinson and Karon, 2000; Temkin-Greener, 2001)
have produced similar results, while samples drawn from these studies have studied
different groups of Medicare beneficiaries.
Predictive ratio is another measure used to evaluate model performance of
risk-adjustment models. The calculation of predictive ratio is based on the formula:
predictive ratio = average medical costs predicted by risk-adjustment models divided
by the average actual medical costs. Since we evaluate risk-adjustment models by
their capacity to predict actual medical costs, a predictive ratio close to 1 indicates
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better model performance than a value that differs significantly from 1. Consistent
findings (Ellis et al., 1996; Health Care Financing Administration, 1999; Pope et al.,
2000; Riley, 2000) show that the PIPDCG model has predictive ratios closer to 1 in
different subgroups of Medicare beneficiaries than the AAPCC model. For example,
Pope and colleagues (2000) report that the predictive ratios are 2.57, 1.88, 1.35,
0.96, and 0.47, respectively, for five subgroups of Medicare beneficiaries according
to their medical costs in the AAPCC model, compared with 2.09, 1.54, 1.10, 0.84,
and 0.75 in the PIPDCG model. The PIPDCG model has a better predictive ratio in all
subgroups except the group whose medical costs fall within a range of 60 to 80
percent of the highest annual medical expense of Medicare beneficiaries. The PIPDCG
model also outperforms the others for all chronic conditions and for frail elders with
functional status difficulties. Ellis et al. (1996) and Riley (2000) found the PIPDCG
model has a better predictive ratio in subgroups of Medicare beneficiaries who have
impairment of 1-2, 3-4, and 5-6 ADLs. These results were later confirmed in a study
by Pope and colleagues (2000).
As the first diagnosis-based model incorporated into the Medicare capitation
payment system, the PIPDCG model has demonstrated more predictive accuracy
than the AAPCC model. However, the R2 value is far below the ideal value (Pope et
al., 2000). Other models have been found to be more competitive in predicting the
variance of future medical costs. For example, the HCC model R2 value of 8.08
percent was found to be better than the PIPDCG model’s R2 value of 5.53 percent
(Ellis et al., 1996).
The PIPDCG model has been criticized by researchers (Miller and Luft, 1997;
Pope et al., 2000; Health Care Financing Administration, 1999) for several
shortcomings: First, the data source for the development of the PIPDCG model is
inpatient data only. Both ambulatory and outpatient data can have significant effects
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on the prediction of future medical costs but these data are not used in the PIPDCG
model. Health plans can be more profitable by hospitalizing Medicare HMO enrollees
who actually only need outpatient or ambulatory services because inpatient medical
care is much more expensive than outpatient services. Second, only the primary
diagnosis is used to evaluate patients’ health condition in hospitalization data, while
other diagnoses associated with significant increases in future medical costs are not
counted. The HCC model incorporates more information about diagnoses in the riskadjustment model.
Researchers (Ellis et al., 1996; Ash et al., 1998; Pope et al., 1998) developed
and examined the HCC model in the late 1990s. The HCC model, as a type of riskadjustment model that can use information from outpatient and long-term care data,
has more predictive power than the PIPDCG model based solely on inpatient data
(Ellis et al., 1996).
Both the HCC model and the PIPDCG model have been developed from
15,000 ICD-9-CM codes because ICD-9-CM codes are generally used in all types of
data from claims submitted by hospitals and physicians’ offices. Compared with 172
PIPDxGs in the PIPDCG model, in the HCC model there are 543 DxGROUPs clustered
from ICD-9-CM codes. Each DxGROUP refers to a group of clinically related diseases
and symptoms. Furthermore, 543 DxGROUPs are classified into 118 Condition
Categories (CC) and each CC includes DxGROUPs with similar predicted medical
costs. Advantages of CCs over PIPDCG categories are: (1) there are more CCs in the
HCC model than PIPDCG categories in the PIPDCG model, hence the HCC model sets
a clearer criterion for coding diagnoses from raw data. Since the PIPDCG model has
26 PIPDCG categories only making it easier for health plans to intentionally change a
lower PIPDCG rank to a higher PIPDCG rank linked with higher medical costs thus
increasing profits. The PIPDCG model has obscure classification criteria for some
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medical disorders because of its few categories. The categorization of CCs is more
likely to be accurate than is the case for PIPDCG categories preventing a health plan
from gaming the capitation payment system by manipulating diagnostic coding. (2)
CCs are specifically designed for practical use on all types of data and therefore are
more appropriate for this purpose. Since ambulatory and outpatient data are
submitted by hospitals and physicians’ offices, the HCC model has the advantage of
using all available information. (3) The HCC model counts multiple diagnoses, while
the PIPDCG model counts only the primary diagnosis. Under the capitation payment
system based on the PIPDCG model, health plans that have Medicare beneficiaries
with multiple health problems are significantly underpaid because only treatment for
the primary medical problem is reimbursed in the PIPDCG model. Pope and
colleagues (2000) report that the predictive ratios for Medicare beneficiaries with two
admissions and beneficiaries with three or more admissions are 0.91 and 0.69
respectively. However, the predictive ratios for Medicare beneficiaries with zero and
beneficiaries with one admission were 1.07 and 1.02 respectively, which overpredicts the true value. Although patients can be hospitalized several times with the
same diagnosis, it is more likely patients are admitted to hospital with different
diagnoses. Hence, evidence that health plans enrolling patients with multiple hospital
admissions are underpaid indicates that the PIPDCG model underestimates actual
medical costs of patients with multiple diagnoses. These results are consistent with
those found in other studies (Ellis et al., 1996; Health Care Financing Administration,
1999).
Demographic adjusters of the HCC model are slightly different from those of
the PIPDCG model. Age is clustered into 15 categories: 0-5 years, 6-12 years, 13-17
years, 18-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, 65-69
years, 70-74 years, 75-79 years, 80-84 years, 85-89 years, 90-94 years, and 95
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years or over (Ash et al., 2000). In the PIPDCG model, age categories are 0-34
years, 35-44 years, 45-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74
years, 75-79 years, 80-84 years, 85-89 years, 90-94 years, and 95 years or over
(Pope et al., 2000). The PIPDCG model divides the 55-64 years category into two
sub-categories: the 55-59 years category and the 60-64 years category. The
“Medicaid status” variable is added to the HCC model. Unlike the PIPDCG model,
there are five eligibility categories in the HCC model: blind/disabled, other medical
problems, poverty, pregnant women, and others.
As health status adjusters of the HCC model, CCs play a different role than
the PIPDCG categories do. Patients can be assigned to multiple CCs, but only one
PIPDCG category. CCs are divided into subgroups and a hierarchy imposed within
each subgroup. For example, the subgroup neoplasm includes seven CCs: CC6 (highcost cancer), CC7 (moderate-cost cancer), CC8 (lower-cost cancers/tumors), CC9
(carcinoma in situ), CC10 (uncertain neoplasm), CC11 (skin cancer, except
melanoma), and CC12 (benign neoplasm). CC6 ranks the highest in this subgroup,
and only CC6 is counted if a patient can be categorized into CC6 and another CC in
the neoplasm subgroup. Only the CC with the highest rank is counted when a patient
has multiple CCs of the same subgroup according to the HCC hierarchy system.
However, CCs from different subgroups can be accumulated at the same time. For
example, CC1 (HIV/AIDS), CC6 (high-cost cancer), and CC19 (liver disease) can be
assigned to the same patient because these CCs are in different subgroups. Meenan
and colleagues (2003) refine the HCC model that has 34 demographic adjusters and
31 CC adjusters, as another version.
The R2 value of the HCC model has a broad range − from 8.1 percent to 15.9
percent (Ash et al., 2000; Ellis et al., 1996; Fishman et al., 2003; Kronick et al.,
2000; McCall and Korb, 1998; Sales et al., 2003). The samples in these studies are
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different, however, the HCC model was found to have the greatest predictive power
when it was compared to the AAPCC model, the PIPDCG model, and the pharmacybased RxRisk model in previous studies (Fishman et al., 2003; Sales et al., 2003).
The investigators (Ellis et al., 1996; Kronick et al., 2000; McCall and Korb, 1998)
conclude that the HCC model has a predictive ratio closer to 1.0 than the AAPCC
model, the PIPDCG model, and the RxRisk model. Ellis and colleagues (1996) report
that the predictive ratios are 1.30, 1.24, 1.14, 0.99, and 0.85 for the five subgroups
of Medicare beneficiaries in the HCC model, while the predictive ratios are 1.92,
1.37, 1.01, 0.78, and 0.85 in the PIPDCG model. The study is based on a national
sample of Medicare beneficiaries, and the HCC model has better predictive ratios
than the PIPDCG model in this study.
A disadvantage of the HCC model is that health plans can abuse the Medicare
capitation payment system (Ash et al., 2000; Ellis et al., 1996). Health plans can
replace lower-ranked CCs with higher ranked ones. Since multiple CCs can be
counted for the same patient, health plans can inflate CC counts and receive more
reimbursements.
As a means of correcting some of the problems evident in diagnosis-based
models, several pharmacy-based RxRisk models have been developed in the past
two decades. Two of them are based on the Chronic Disease Score (Von et al., 1992)
designed by the Center for Health Studies, Group Health Cooperative of Puget Sound
(GHC). Prescription drugs in current medical practice are reviewed by a panel of
physicians and health services researchers, and CDS categories are created by
researchers. Since the original CDS model was related only to adult chronic
conditions, a pediatric CDS model has also been developed by Fishman and Shay
(1999). Based on the CDS and pediatric CDS model, the RxRisk model and the
RxRisk-V model have been developed and discussed in several studies (Gilmer et al.,
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2001; Fishman et al., 2003; Meenan et al., 2003; Sales et al., 2003; Sloan, 2003).
The major difference between the RxRisk model (Fishman et al., 2003;
Meenan et al., 2003; Sales et al., 2003) and the RxRisk-V model (Sales et al., 2003;
Sloan et al., 2003) is the method of categorization. The RxRisk model consists of 28
adult RxRisk factors and 24 pediatric RxRisk factors. Sloan and colleagues (2003)
review RxRisk categories and establish 45 RxRisk-V categories. Two RxRisk
categories are replaced by four RxRisk-V categories: anticoagulation, antiplatelet
agents, ischemic heart disease/angina, and congestive heart failure/hypertension.
Diagnosis-based models, compared with pharmacy-based models, have been
reviewed by investigators (Gilmer et al., 2001; Fishman et al., 2003; Sales et al.,
2003; Sloan et al., 2003). Three disadvantages of diagnosis-based models have been
identified: (1) Some health plans and HMOs do not collect diagnostic data routinely
while pharmacy data is recorded in all claims files. (2) Reliability of diagnoses data
can be questionable because of faulty recording, while pharmacy data are more
reliable. (3) Health plans can become more profitable by gaming capitation payment
systems. There is a general consensus that pharmacy-based models decrease the
possibility of gaming because drugs used in clinical practice must be correctly
recorded by hospitals and physicians’ offices.
Diagnosis-based models, however, do have certain advantages over
pharmacy-based models (Fishman et al., 2003). For example, the HCC model has
more variables than the RxRisk model and the RxRisk-V model, and can identify
more diseases than the RxRisk model and the RxRisk-V model. A shortcoming of
RxRisk and RxRisk-V factors is that they have been developed from outpatient
pharmacy data, and designed for chronic conditions only.
Age and gender are major demographic variables in the RxRisk model and the
RxRisk-V model. On the other hand, the “Medicaid status” variable is not included in
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pharmacy-based models, unlike the HCC model and the PIPDCG model. The critical
outcome of course is the proportion of variance accounted for. The R2 value of the
RxRisk model and the RxRisk-V model has been reported by different researchers
(Fishman et al., 2003; Meenan et al., 2003; Sales et al., 2003; Sloan et al., 2003);
the R2 value for the RxRisk model ranges from 7.7 percent (Fishman et al., 2003) to
11.1 percent (Sales et al., 2003) while the R2 values for the RxRisk-V model ranges
from 10.0 percent (Fishman et al., 2003) to 12.2 percent (Sloan et al., 2003). Sloan
and colleagues (2003) compare the model performance of the RxRisk model with
that of the RxRisk-V model, and report that the RxRisk-V model can explain more
variance of medical expenses. The HCC model has outperformed pharmacy-based
models in earlier studies (Fishman et al., 2003; Sales et al., 2003).
Hypothesis and Research Questions
In the previous studies, researchers typically built a risk adjustment model
based on one class of health condition variables. Some models used HCC adjusters
that utilize information on diagnoses from inpatient and outpatient files. The
diagnosis-based HCC model is the most common risk adjustment model
implemented in the current Medicare and Medicaid capitation payment systems.
However, there are shortfalls of diagnosis-based models in clinical practice. First,
diagnostic variables are just one of several factors which have effects on medical
costs. Consider that two patients with the same bacterial infection may have
different medical costs since one is allergic to inexpensive antibiotics and requires
more expensive medicine. Consequently, the patient with the allergy will have much
higher medical costs than the patient who is treated with less expensive medications.
Additionally, some patients may need costly medicine while others with the same
disease need only generic drugs. Obviously, a risk adjustment model with only
diagnosis-based adjusters will underpredict medical costs of patients with special
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needs. Second, diagnoses can be easily manipulated by health plans since diagnoses
are vague even after patients have been discharged from hospitals.
Pharmacy-based models were developed as possible replacements of
diagnosis-based models. However, pharmaceutical adjusters are only associated with
prescription drug costs among total medical costs. Hence, it is not a good predictor
for overall medical costs. However, pharmaceutical adjusters can provide additional
information if they are incorporated into a risk adjustment model based on diagnostic
adjusters. As mentioned in the earlier context, some patients have to be treated with
more expensive medicine than other patients in the same disease group. Utilizing
information on prescription drug usage can predict medical costs for these patients
more accurately. Moreover, the addition variables in risk adjustment models may
increase predictive power.
The hypothesis of this dissertation is that addition of pharmacy-based risk
adjusters in the HCC model can improve both predictive power and performance in
practical implementation. A good risk adjustment model must be easily implemented
and decrease the likelihood of gaming to the maximum degree. It is assumed the
proposed model having both HCC and RxRisk adjusters will predict medical costs
more accurately. This model can avoid some uncertainty associated with the HCC
model since prescription drug use provides more information about patients’ health
condition. The research questions this dissertation seeks to answer are how RxRisk
adjusters should be entered into the HCC model and how to statistically and clinically
evaluate model performance. The hypothesis that the proposed model can
outperform the HCC model and the RxRisk model is tested and the research
questions posed above are answered.
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Chapter Two
Population
The data for this dissertation was drawn from the administrative claims
generated by 2.3 million Medicaid beneficiaries eligible for the Florida Medicaid
program during State Fiscal Year (SFY) 2002-03 and 2003-04. A Florida SFY begins
in July and ends the following June. SFY 2002-03 is the base year data, which was
used to obtain information for demographic and health status variables. The SFY
2003-04 data is the year 2 data and includes information about medical costs and
eligible months.
Ash and colleagues (2000) subdivide Medicaid enrollees into five groups: (1)
the blind and disabled; (2) beneficiaries with other medical problems; (3) pregnant
women and children; (4) beneficiaries with poverty-related entitlement; (5) and
others; most Medicaid beneficiaries age 65 or over are also eligible for Medicare. For
the purposes of the research reported here, two subpopulations were identified from
the SFY 2002-03 Florida Medicaid data. The first subpopulation is Medicaid
beneficiaries who are age 65 and older. The second subpopulation is disabled adult
Medicaid beneficiaries who are older than 18 and younger than 65 years old. There
were 242,193 enrollees in the aged adult subpopulation and 144,846 enrollees in the
disabled adult subpopulation. The SFY 2002-03 Florida Medicaid data is referred to as
the total Medicaid population in this dissertation.
Methods
The outcome variable is the Per Member Per Month (PMPM) cost for all
services reimbursed by Medicaid for each beneficiary during SFY 2003-04. In order
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to calculate PMPM, all claims for each Medicaid beneficiary were summed to obtain
the annual total medical cost. This was divided by the Medicaid eligible months for
the same beneficiary during SFY 2003-04. The PMPM cost includes medical expenses
for hospitalization, prescription drugs, outpatient services, and other acute and longterm care services. Base year data and year 2 data were merged to build multiple
linear regression models. The combined data is used to establish model structure and
measure model performance. The form of regression models is:
Y = α + β1X1 + β2X2 + β3X3 + β4X4 + … + βnXn ,
where Y represents the PMPM cost for each Medicaid beneficiary during SFY 2003-04
and X1 - Xn represent the various demographic and health condition variables.
The HCC model and the PIPDCG model are both diagnosis-based riskadjustment models. The HCC model can include multiple diagnoses from different
data resources, while the PIPDCG model uses only the primary diagnoses during
hospitalization. Since the HCC model uses more information about diagnoses and has
more predictive power, the risk-adjustment model presented in this dissertation uses
the CC categories in the HCC model as the foundation for its diagnostic variables.
CC categories are developed from Diagnostic Groups (DxGroups), which are
created from more than 15,000 International Classification of Diseases, 9th Revision,
Clinical modification (ICD-9-CM) codes. There are 543 DxGroups, and each DxGroup
includes a cluster of similar clinical diseases. The classification of DxGroups is made
by researchers according to clinical criteria and physicians’ experience. CC categories
are created to consist of DxGroups with similar medical costs. Hence, diseases in a
CC category usually have clinical homogeneity and similar medical costs. In this
dissertation, 70 CC categories are included in the HCC model and the proposed
model.
Only diagnostic codes in claims files were used to infer diagnoses for this
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study. Medicaid beneficiaries can have multiple diagnoses, and hence can have
multiple CCs. In the proposed risk-adjustment model, the diagnosis-based health
condition variables consist only of HCC variables based on CC categories. Ash and
colleagues (2000) examined the list of CC categories in order to avoid “DCG creep,”
a coding practice that health plans employ to intentionally change diagnoses with
lower predicted capitation payment to diagnoses having higher payment. Some CC
categories are excluded and hierarchies are imposed to decrease frequency of vague
coding and intentional coding proliferation (Ash et al., 2000). Every HCC variable in
the proposed model corresponds to a CC category, which is clearly distinguished
from other CC categories. The list of HCC variables can be seen in Table 1.
Hierarchies contain only the medical condition associated with the highest medical
costs in risk-adjustment models when patients have several clinically related medical
problems. For example, CC7 is “moderate–cost cancer” and has a higher rank than
CC8 (lower–cost cancer) in the HCC hierarchy system. Hence, only moderate–cost
cancer is used to predict medical expense if a patient has both moderate–cost cancer
and lower–cost cancer. When a patient has several medical problems in the same
hierarchy, only the highest-ranked disease is used for the prediction. For example,
only CC7 will be retained in risk-adjustment models when a patient has CC7, CC8,
and CC9 (carcinoma in situ). The HCC hierarchy system can be seen in Table 2.
After imposing hierarchies in risk-adjustment models, the risk-adjustment
model assumes the possibility of variable inflation and inappropriate coding practice
can be well-controlled. When a patient has multiple medical problems corresponding
to several CCs in the same hierarchy, only the highest-ranked CC is used in riskadjustment models. CCs with smaller numbers are higher-ranked CCs. For example,
the order in the neoplasm1 hierarchy is: CC7 > CC8 > CC9 > CC10.
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Table 1: The List of HCC Variables
HCC Number
HCC1
HCC2
HCC5
HCC7
HCC8
HCC9
HCC10
HCC15
HCC16
HCC17
HCC18
HCC19
HCC21
HCC25
HCC26
HCC27
HCC31
HCC32
HCC33
HCC37
HCC38
HCC44
HCC45
HCC51
HCC52
HCC54
HCC55
HCC67
HCC68
HCC69
HCC70
HCC71
HCC72
HCC73
HCC74
HCC75
HCC77
HCC78
HCC79
HCC80
HCC81
HCC82
HCC83
HCC92
HCC95
HCC96
HCC100
HCC101
HCC104

Disease Categories
HIV/AIDS
Septicemia/Shock
Opportunistic Infections
Metastatic Cancer and Acute Leukemia
Lung, Upper Digestive Tract, and Other Severe Cancers
Lymphatic, Head and Neck, Brain, and Other Major Cancers
Breast, Prostate, Colorectal and Other Cancers and Tumors
Diabetes with Renal or Peripheral Circulatory Manifestation
Diabetes with Neurologic or Other Specified Manifestation
Diabetes with Acute Complications
Diabetes with Ophthalmologic or Unspecified Manifestation
Diabetes without Complication
Protein-Calorie Malnutrition
End-Stage Liver Disease
Cirrhosis of Liver
Chronic Hepatitis
Intestinal Obstruction/Perforation
Pancreatic Disease
Inflammatory Bowel Disease
Bone/Joint/Muscle Infections/Necrosis
Rheumatoid Arthritis and Inflammatory Connective Tissue Disease
Severe Hematological Disorders
Disorders of Immunity
Drug/Alcohol Psychosis
Drug/Alcohol Dependence
Schizophrenia
Major Depressive, Bipolar, and Paranoid Disorders
Quadriplegia, Other Extensive Paralysis
Paraplegia
Spinal Cord Disorders/Injuries
Muscular Dystrophy
Polyneuropathy
Multiple Sclerosis
Parkinson’s and Huntington’s Diseases
Seizure Disorders and Convulsions
Coma, Brain Compression/Anoxic Damage
Respirator Dependence/Tracheotomy Status
Respiratory Arrest
Cardio-Respiratory Failure and Shock
Congestive Heart Failure
Acute Myocardial Infarction
Unstable Angina and Other Acute Ischemic Heart Disease
Angina Pectoris/Old Myocardial Infarction
Specified Heart Arrhythmias
Cerebral Hemorrhage
Ischemic or Unspecified Stroke
Hemiplegia/Hemiparesis
Cerebral Palsy and Other Paralytic Syndromes
Vascular Disease with Complications
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HCC105
Vascular Disease
HCC107
Cystic Fibrosis
HCC108
Chronic Obstructive Pulmonary Disease
HCC111
Aspiration and Specified Bacterial Pneumonias
HCC112
Pneumococcal Pneumonia, Emphysema, Lung Abscess
HCC119
Proliferative Diabetic Retinopathy and Vitreous Hemorrhage
HCC130
Dialysis Status
HCC131
Renal Failure
HCC132
Nephritis
HCC148
Decubitus Ulcer of Skin
HCC149
Chronic Ulcer of Skin, Except Decubitus
HCC150
Extensive Third-Degree Burns
HCC154
Severe Head Injury
HCC155
Major Head Injury
HCC157
Vertebral Fractures without Spinal Cord Injury
HCC158
Hip Fracture/Dislocation
HCC161
Traumatic Amputation
HCC164
Major Complications of Medical Care and Trauma
HCC174
Major Organ Transplant Status
HCC176
Artificial Openings for Feeding or Elimination
HCC177
Amputation Status, Lower Limb/Amputation Complications
Note: The list of HCC categories are copied from description of 2007 CMS-HCC
software downloaded from the website of Center for Medicare and Medicaid Services.
Some CC categories are excluded because they have vague clinical health
conditions or did not have significant effects on the prediction of medical costs.
Seventy HCC variables are included in the HCC model and are used in this
dissertation’s proposed model.
The creation of HCC variables is based on the 2007 version of the CMS-HCC
software. The CMS version of the HCC model has been incorporated into the
Medicare capitation payment system and evaluated by researchers (Pope et al.,
2004).
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Table 2: The HCC Hierarchy System
Hierarchies
Infection
Neoplasm1
Neoplasm2
Neoplasm3
Diabetes1
Diabetes2
Diabetes3
Diabetes4
Liver1
Liver2
Agina1
Psychiatric
Spinal1
Spinal2
Spinal3
Arrest1
Arrest2
Heart1
Heart2
CVD1
CVD2
Vascular1
Lung1
Lung2
Urinary1
Urinary2
Skin1
Injury1
Injury2

CC Categories
CC5, CC112
CC7, CC8, CC9, CC10
CC8, CC9, CC10
CC9, CC10
CC15, CC16, CC17, CC18, CC19
CC16, CC17, CC18, CC19
CC17, CC18, CC19
CC18, CC19
CC25, CC26, CC27
CC26, CC27
CC51, CC52
CC54, CC55
CC67, CC68, CC69, CC100, CC101, CC157
CC68, CC69, CC100, CC101, CC157
CC69, CC157
CC77, CC78, CC79
CC78, CC79
CC81, CC82, CC83
CC82, CC83
CC95, CC96
CC100, CC101
CC104, CC105, CC149
CC107, CC108
CC111, CC112
CC130, CC131, CC132
CC131, CC132
CC148, CC149
CC154, CC75, CC155
CC161, CC177

Pharmacy-based risk adjusters are included in the dissertation model in
addition to the diagnosis-based adjusters. For comparison purposes, the results also
include a model with only pharmacy-based variables, a version of the RxRisk model.
Pharmacy-based risk adjusters are developed from the Chronic Disease Score (CDS),
defined by Clark and colleagues (1995). Putnam and colleagues (2002) compare four
versions of the Chronic Disease Score and report that the Clark version performs
better. The CDS categories are developed from the National Drug Code (NDC).
Florida Medicaid claims files have a NDC variable that can provide information about
prescription drug usage. Since Medicaid beneficiaries can have multiple prescription
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drug claims, they are assigned to one or several CDS categories according to the
number of claims. Like CCs, CDS categories are not mutually exclusive. However,
there is no hierarchy imposed on the CDS categories; only 29 CDS variables were
available for the dissertation model and the RxRisk model in contrast to the 70 HCC
variables.
The CDS categories and corresponding HCC categories are listed in Table 3.
The work for this dissertation reviewed all 29 CDS categories and finds that 12
categories cover the same diseases with certain CC categories.
These CDS categories are not duplicated in the dissertation model. When a
Medicaid beneficiary uses prescription drugs in one of these CDS categories, the
value of the corresponding HCC variable is set to 1, indicating that the patient has a
diagnosis related to the HCC variables, even if the original value HCC is 0. For
example, the value of HCC1 (HIV/AIDS) is set to 1 when the original value of HCC1
is 0 but the Medicaid beneficiary is prescribed drugs in the A3 (AIDS) category.
Six CDS categories are not used in the proposed model because they correspond to
multiple CC categories. In this case, a patient in any of these CDS categories can be
assigned to one of the corresponding CC categories. If we add these CDS categories
to our models, the predicted medical costs might be inappropriately inflated through
a coding maneuver by the health plans. The six CDS categories excluded from our
models are: A10 (diabetes), A15 (heart disease /hypertension), A20 (malignancies),
A7 (cardiac disease), A24 (psychotic illness), and A8 (coronary/peripheral vascular
disease). Research for this dissertation created CDS variables for the 11 CDS
categories without corresponding HCC variables and added them directly into the
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Table 3: CDS Disease Categories with the Corresponding HCC Categories
Diseases
Cystic fibrosis
Diabetes
Epilepsy
Gastric acid disorder
Glaucoma
Gout
Heart disease
Hyperlipidemia
Hypertension
Inflammatory Bowel Disease
Liver failure
End stage renal disease
Malignancies
Pain
Pain and inflammation
Parkinson’s disease
Psychotic illness
Renal disease
Rheumatoid arthritis
Thyroid disorder
Transplant
Tuberculosis
AIDS
Anxiety and tension
Asthma
Bipolar disorder
Cardiac disease
Coronary disease
Depression

CDS Category
A1
A10
A11
A12
A13
A14
A15
A16
A17
A18
A19
A2
A20
A21
A22
A23
A24
A25
A26
A27
A28
A29
A3
A4
A5
A6
A7
A8
A9

HCC Category
HCC107
HCC15, 16, 17, 18, 19
HCC74
None
None
None
HCC80, 81, 82, 83, 92
None
None
HCC33
HCC25
HCC131
HCC7, 8, 9, 10
None
None
HCC73
HCC54
None
HCC38
None
HCC174
None
HCC1
None
None
HCC55
HCC80, 81, 82, 83, 92
HCC81, 82, 83
HCC55

dissertation model.
The demographic parts of the HCC model, the RxRisk model, and the
dissertation model include the same variables. There are 24 age-sex crossing
variables that represent 24 demographic groups with different age and gender
characteristics. These variables are:
•

“18-24-year-old female” group

•

“25-34-year-old female” group

•

“35-44-year-old female” group
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•

“45-54-year-old female” group

•

“55-64-year-old female” group

•

“65-69-year-old female” group

•

“70-74-year-old female” group

•

“75-79-year-old female” group

•

“80-84-year-old female” group

•

“85-89-year-old female” group

•

“90-94-year-old female” group

•

“95-year-old or over female” group

•

“18-24-year-old male” group

•

“25-34-year-old male” group

•

“35-44-year-old male” group

•

“45-54-year-old male” group

•

“55-64-year-old male” group

•

“65-69-year-old male” group

•

“70-74-year-old male” group

•

“75-79-year-old male” group

•

“80-84-year-old male” group

•

“85-89-year-old male” group

•

“90-94-year-old male” group

•

“95-year-old or over male” group

Medicaid covers medically needy younger adults as well as the elderly, and
the prevalence of certain diseases can differ significantly among various age-gender
groups. Moreover, there can be a large gap in the average medical costs of the
younger and older beneficiaries, even if they have the same medical problems.
Because the dissertation model uses information about demographic characteristics
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to predict the year 2 medical expenses of those who are healthy in the base year,
demographic variables have an important role in risk-adjustment.
Models with only demographic variables have low predictive power (Ash et al.,
1989; Ellis et al., 1996; Newhouse, 1986), which was the primary motivation for
including the health condition variables mentioned above.
Multiple linear regression models were built for analyses in this dissertation.
The form of the regression models is:
Y = α + β1X1 + β2X2 + β3X3 + … + βnXn ,
where Y represents the total amount of medical costs in the 2003-2004 year, X1 to Xn
represent demographic, HCC, and CDS variables from SFY 2002-03 Medicaid claims.
In other words, baseline year claims are used to flag the presence of health
conditions, which are used to predict year 2 claims. A regression was run on the
Medicaid populations and the entire adult aged and disabled population using the
version 8 of the SAS software. The HCC and RxRisk models were run for comparison
purposes. Both models have the same form as the dissertation model.
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Chapter Three
Results
The SFY 2002–03 Florida Medicaid data includes 2,849,493 Florida Medicaid
beneficiaries. Eighty-one percent (N = 2,310,464) of them were eligible for Medicaid
for at least one month in SFY 2003–04. The Medicaid population for this study
included 2,310,464 Medicaid beneficiaries during SFY 2002-03. The young
subpopulation of disabled adults consisted of 144,846 beneficiaries. The aged
subpopulation had 242,193 Medicaid beneficiaries in SFY 2002-03.
In the overall Medicaid population, 59.35 percent of beneficiaries (N =
1,371,223) were female enrollees. Eighty-nine percent of beneficiaries (N =
2,007,004) were younger than 65 years old.
In the aged subpopulation, 71.44 percent of beneficiaries (N = 173,028) are
female enrollees. The “70-74-year-old female” category has the largest proportion
(15.36 percent), and the “75-79-year-old female” is the second-largest group (14.65
percent) among all demographic categories. Eighty-seven percent of the
beneficiaries were eligible for Medicaid for 12 months in SFY 2003–04. Their PMPM
total Medicaid claims was $933.01 in SFY 2003–04.
In the young subpopulation of disabled adults, 57.90 percent of beneficiaries
(N = 83,861) are female enrollees. The “55-64-year-old female” category has the
largest proportion (15.84 percent), and the “45-54-year-old female” is the secondlargest group (14.91 percent) among all demographic categories. Ninety-one percent
of the beneficiaries were eligible for Medicaid for 12 months in SFY 2003–04. Their
PMPM total Medicaid claims was $1,120.09 in SFY 2003–04.
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Model Performance
To validate the predictive power of the proposed models, the R2 value of the
models is compared. Since the coefficient of each independent variable in the riskadjustment model represents the average increase in the PMPM Medicaid claims, the
coefficients associated with each variable are also compared. Table 4 lists the
summary statistics for the proposed model, the HCC model, and the RxRisk model
for the Medicaid population.
The proposed model was found to have the highest R2 value among the three
models. The adjusted R2 value of the proposed model, which compensates for adding
independent variables, is 0.28. This compares with 0.24 for the HCC model and 0.21
for the RxRisk model. The proposed model also had the lowest Root Mean Square
Error (RMSE = 944.42), which indicates variance about the predicted PMPM total
Medicaid claims; models with a lower RMSE make better forecasts. The HCC model
was found to have a higher R2 value and lower RMSE than the RxRisk model,
indicating that diagnosis-based risk-adjustors are better predictors of medical costs
than prescription-based risk-adjusters.
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Table 4: Statistics for the Proposed Model, the HCC Model, and the RxRisk Model for
the Medicaid population

Statistics
Number of Enrollees
Number of Predictors
R2
Validated R2
Root Mean Square Error
Variables
Intercept

Proposed
Model

HCC
Model

2,310,464
111
0.28
0.28
944.42

2,310,464
99
0.24
0.24
970.67

RxRisk
Model
2,310,464
58
0.21
0.21
991.63

PM
1421.96

PM
1680.57

PM
1309.51

-1162.43
-1166.16
-1163.63
-1098.21
-1057.35
-1203.56
-1127.53
-947.78
-637.78
-270.28
56.62
392.37

-1402.50
-1387.31
-1316.02
-1150.19
-1118.08
-1292.31
-1198.10
-993.70
-635.09
-221.92
127.50
447.66

-1031.62
-1036.46
-1019.74
-934.94
-889.56
-1136.32
-1083.46
-914.85
-626.84
-277.77
34.29
371.91

-1179.93
-1080.06
-1056.33
-955.48
-883.14
-1121.33
-1062.68
-917.62
-686.92
-359.07
161.19
-

-1397.55
-1244.44
-1147.85
-1034.14
-1004.20
-1253.70
-1181.41
-1007.34
-729.68
-339.75
-124.73
-

-982.36
-886.34
-874.32
-750.79
-650.95
-1029.84
-999.03
-866.76
-657.33
-364.58
-163.78
-

904.17
566.58
846.56

1074.94
601.91
845.09

-

Female
18-24 Years
25–34 Years
35-44 Years
45–54 Years
55-64 Years
65–69 Years
70-74 Years
75–79 Years
80-84 Years
85–89 Years
90-94 Years
95 Years or Over
Male
18-24 Years
25–34 Years
35-44 Years
45–54 Years
55-64 Years
65–69 Years
70-74 Years
75–79 Years
80-84 Years
85–89 Years
90-94 Years
95 Years or over
HCC variables
Infection
HCC1
HCC2
HCC5
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Neoplasm
HCC7
HCC8
HCC9
HCC10

1190.18
462.58
218.04
57.77

1271.69
543.77
284.68
82.53

-

Endocrinal Disorders
HCC15
HCC16
HCC17
HCC18
HCC19
HCC21

709.10
306.12
247.93
214.37
103.87
656.54

804.79
400.57
289.61
278.80
139.51
653.71

-

Gastrointestinal
Disorders
HCC25
HCC26
HCC27
HCC31
HCC32
HCC33

534.77
228.48
143.71
381.66
247.78
67.40

642.19
330.40
247.95
454.35
273.13
103.81

-

Connective Tissue
Disease
HCC37
HCC38

195.30
-6.19

213.85
83.54

-

1151.22
396.44

1162.97
447.59

-

Psychiatric Disorders
HCC51
HCC52
HCC54
HCC55

0.57
39.63
440.64
166.79

85.51
126.55
725.80
364.30

-

Spinal Cord Disorders
HCC67
HCC68
HCC69

2416.65
961.39
476.58

2488.53
1027.30
506.94

-

Neurological
Disorders
HCC70
HCC71
HCC72
HCC73
HCC74

1333.61
127.42
475.80
494.69
588.76

1301.52
289.57
672.08
813.15
815.30

-

Hematological
Disorders
HCC44
HCC45
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HCC75

1348.61

1334.25

-

Respiratory Disorders
HCC77
HCC78

3896.12
597.94

3922.82
665.95

-

Cardiac Diseases
HCC79
HCC80
HCC81
HCC82
HCC83
HCC92

410.70
369.33
117.29
-20.23
-154.07
131.78

451.56
414.59
55.77
-15.02
-127.56
129.02

-

Cerebral and
Vascular Diseases
HCC95
HCC96
HCC100
HCC101
HCC104
HCC105

194.98
457.79
500.44
1707.94
420.80
343.28

191.24
537.97
524.37
1777.23
455.21
395.69

-

Pulmonary Diseases
HCC107
HCC108
HCC111
HCC112

19.53
-14.13
952.72
196.08

1574.13
132.68
911.62
209.27

-

Eye Disorders
HCC119

-37.00

-22.28

-

Renal Disorders
HCC130
HCC131
HCC132

692.33
487.36
183.03

1127.53
536.02
236.06

-

Skin Disorders
HCC148
HCC149
HCC150

610.57
424.29
207.37

721.78
510.83
234.00

-

Injury
HCC154
HCC155
HCC157
HCC158
HCC161
HCC164

864.19
140.17
124.15
357.44
90.82
387.74

926.78
192.38
170.77
434.85
181.45
436.66

-

Others
HCC174

256.27

918.76

-
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HCC176
HCC177

1745.14
646.77

1827.30
699.96

-

CDS Variables
18.14
A1
1086.18
A2
989.09
A3
163.00
224.32
A4
96.43
143.73
A5
-58.46
A6
284.29
A7
84.03
A8
114.01
A9
190.25
A10
740.76
A11
157.33
219.19
A12
32.01
14.63
A13
23.47
-29.57
A14
-72.46
A15
-117.34
-201.69
A16
54.20
41.91
A17
79.34
A18
745.49
A19
428.62
A20
-32.82
9.23
A21
-150.23
-181.94
A22
454.67
A23
452.24
A24
592.96
798.12
A25
11.51
A26
264.13
231.57
A27
211.83
A28
433.97
725.61
A29
Notes: PM is Parameter. “-” indicates a variable that is not relevant for a particular
model. Male patients age 95 or over are used as baseline in our models. The units of
all medical costs are dollars.
The “age 95 years or over male” group was used as the baseline age-gender
group in all three models. Future medical costs peak at age 45 to 64 years, and then
decrease between age 65 and 69 years. After age 65 to 69 years, future medical
costs increase again and have a positive relationship to age.
The HCC variables were divided into 18 groups and compared parameters
within each group in both the proposed model and the HCC model. Three categories
fell within the “infection” group: HCC1 (HIV/AIDS), HCC2 (septicemia/shock), and
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HCC5 (opportunistic infections). In the proposed model, Acquired Immune Deficiency
Syndrome (AIDS) was associated with the highest increase in future medical costs
among the three diseases, which was $904.17 in the proposed model and $1,074.94
in the HCC model.
The “neoplasm” group includes HCC7 (metastatic cancer and acute leukemia),
HCC8 (lung, upper digestive tract, and other severe cancers), HCC9 (lymphatic,
heart and neck, brain, and other major cancers), and HCC10 (breast, prostate,
colorectal and other cancers and tumors). Their ranks were positively associated with
future medical costs. For example, metastatic cancer and acute leukemia increase
PMPM medical costs by $1,190.18 in the proposed model after other factors are
controlled, and by $1,271.69 in the HCC model. Breast, prostate, and colorectal
cancers are associated with a lower increase in PMPM medical costs than lung, upper
digestive tract, and brain cancers.
The “endocrinal disorders” group includes HCC15 (diabetes with renal or
peripheral circulatory manifestation), HCC16 (diabetes with neurological or other
specified manifestation), HCC17 (diabetes with acute complications), HCC18
(diabetes with ophthalmologic or unspecified manifestation), HCC19 (diabetes
without complication) and HCC21 (protein-calorie malnutrition). Among all diabetes
categories, diabetes with renal or peripheral circulatory manifestation was associated
with the highest increase in the PMPM medical cost, which is $709.10 in the
proposed model and $804.79 in the HCC model. Protein-calorie malnutrition is also
associated with relatively high PMPM medical costs in the “endocrinal disorders”
group.
The “gastrointestinal disorders” group consisted of six HCC variables: HCC25
(end-stage liver disease), HCC26 (cirrhosis of the liver), HCC27 (chronic hepatitis),
HCC31 (intestinal obstruction/perforation), HCC32 (pancreatic disease), and HCC33
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(inflammatory bowel disease). End-stage liver disease was associated with the
highest increase in the PMPM medical cost among all gastrointestinal disorders,
which is $534.77 in the proposed model and $642.19 in the HCC model.
The “connective tissue disease” group includes HCC37 (bone/joint/muscle
infections/necrosis) and HCC38 (rheumatoid arthritis and inflammatory connective
tissue disease). They were associated with a moderate increase in the PMPM medical
cost.
Two HCC variables fall into the “hematological disorders” group: HCC44
(severe hematological disorders) and HCC45 (immune disorders). Severe
hematological disorders are significantly associated with a high increase in the PMPM
medical cost, which is $1,152.22 in the proposed model and $1,162.98 in the HCC
model.
The “psychiatric disorders” group includes four categories: HCC51
(drug/alcohol psychosis), HCC52 (drug/alcohol dependence), HCC54 (schizophrenia),
and HCC55 (major depressive, bipolar, and paranoid disorders). Schizophrenia is
associated with the highest increase in the PMPM medical cost in this group, which is
$440.64 in the proposed model and $725.80 in the HCC model.
The “spinal cord disorders” group consists of HCC67 (quadriplegia, other
extensive paralysis), HCC68 (paraplegia), and HCC69 (spinal cord
disorders/injuries). These are associated with a high increase in the PMPM medical
cost, especially quadriplegia and paraplegia. Quadriplegia increases the PMPM
medical cost by $2,416.65 in the proposed model and $2,488.53 in the HCC model.
The “neurological disorders” group includes HCC70 (muscular dystrophy),
HCC71 (polyneuropathy), HCC72 (multiple sclerosis), HCC73 (Parkinson’s and
Huntington’s Disease), HCC74 (seizure disorders and convulsions) and HCC75
(coma, brain compression/anoxic damage). Muscular dystrophy and coma are both
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associated with more than a $1,300 increase in the PMPM medical cost.
The “respiratory disorders” group consists of HCC77 (respiratory
dependence/tracheotomy status) and HCC78 (respiratory arrest). Respiratory
dependence or tracheotomy status is associated with the highest increase in the
PMPM medical cost among all diagnoses, $3,896.12 in the proposed model, and
$3,922 in the HCC model.
The “cardiac diseases” group includes six categories: HCC79 (cardiorespiratory failure and shock), HCC80 (congestive heart failure), HCC81 (acute
myocardial infarction), HCC82 (unstable angina and other acute ischemic heart
disease), HCC83 (angina pectoris/old myocardial infarction), and HCC92 (specified
heart arrhythmias). Cardio-respiratory failure and shock is significantly associated
with the highest PMPM medical cost, $410.70 in the proposed model, and $451.56 in
the HCC model.
The “cerebral and vascular diseases” group includes HCC95 (cerebral
hemorrhage), HCC96 (ischemic or unspecified stroke), HCC100
(hemiplegia/hemiparesis), HCC101 (cerebral palsy and other paralytic syndromes),
HCC104 (vascular disease with complications), and HCC105 (vascular disease).
Cerebral palsy and other paralytic syndromes are associated with the highest
increase in the PMPM medical cost, $1,707.94 in the proposed model, and $1,777.23
in the HCC model.
The “pulmonary diseases” group consists of four categories: HCC107 (cystic
fibrosis), HCC108 (chronic obstructive pulmonary disease), HCC111 (aspiration and
specified bacterial pneumonias), HCC112 (pneumococcal pneumonia, empyema, and
lung abscess). Parameters of cystic fibrosis are very different for the proposed model
and the HCC model − $19.53 and $1,574.13, respectively.
There is only one category in the “eye disorders” group: HCC119 (proliferative

36

diabetic retinopathy and vitreous hemorrhage). It is associated with a negative
increase in the PMPM medical cost.
The “renal disorders” group includes HCC130 (dialysis status), HCC131 (renal
failure), and HCC132 (nephritis). Dialysis is associated with the highest increase in
the PMPM medical cost in this group, which is $692.33 in the proposed model and
$1,127.53 in the HCC model.
The “skin disorders” group consists of HCC148 (decubitus ulcer of the skin),
HCC149 (chronic ulcer of the skin, except decubitus) and HCC150 (extensive thirddegree burns). Decubitus skin ulcer is associated with the highest increase in the
PMPM medical cost in this group, which is $610.57 in the proposed model and
$721.78 in the HCC model.
The “injury” group includes HCC154 (severe head injury), HCC155 (major
head injury), HCC157 (vertebral fractures w/o spinal cord injury), HCC158 (hip
fracture/dislocation), HCC161 (traumatic amputation), and HCC164 (major
complications of medical care and trauma). Severe head injury is associated with a
$864.19 increase in the proposed model and a $926.78 increase in the HCC model,
which are higher than those of other disorders in the “injury” group.
Several HCC categories are assigned to the “others” group: HCC174 (major
organ transplant status), HCC176 (artificial openings for feeding or elimination), and
HCC177 (amputation status, lower limb/amputation complications). Artificial
openings for feeding or elimination and amputation status are significantly associated
with relatively high increase in the PMPM medical cost. Artificial openings for feeding
or elimination increase PMPM medical cost by $1,745.14 in the proposed model and
$1,827.30 in the HCC model.
Twenty-nine CDS variables are added into the RxRisk model and 12 of them
are also independent variables in the proposed model in this dissertation. They are:
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A12 (gastric acid disorder), A13 (glaucoma), A14 (gout), A16 (hyperlipidemia), A21
(pain), A22 (pain and inflammation), A25 (renal disease), A27 (thyroid disorder),
A29 (tuberculosis), A4 (anxiety and tension), A5 (asthma), and A17 (hypertension).
In the RxRisk model, these variables are significantly associated with a high increase
in the PMPM medical cost: end-stage renal disease ($1,086.18), epilepsy ($740.76),
liver failure ($745.49), renal disease ($798.12), and tuberculosis ($725.61). In the
proposed model, renal disease and tuberculosis are also associated with high
increases in PMPM medical costs, $592.96 and $433.97, respectively.
The aged subpopulation included 242,192 Medicaid enrollees aged 65 and
above. The proposed model has the best predictive performance since its R2 value
(R2 = 0.32) and RMSE (RMSE = 1,174.92) is the highest among all models for the
aged population. The pharmacy-based RxRisk model has slightly lower R2 value (R2 =
0.30) and higher RMSE (RMSE = 1,187.07) than the proposed model. The HCC
model has relatively poorer predictive performance with lower R2 value (R2 = 0.17)
and higher RMSE (RMSE = 1,299.12)
In all three models for the aged subpopulation, age has a strong and linear
effect on PMPM total Medicaid claims for both male and female groups. The PMPM
medical costs increase significantly with a five-year increment of age. Among all agegender groups with beneficiaries aged 80 or above only, female beneficiaries have
higher average PMPM medical costs than male beneficiaries. In the proposed model,
the older male beneficiaries aged under 80 have higher PMPM medical costs than
their female counterparts. The results of statistics for the aged subpopulation are
shown in Table 5.
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Table 5: Compared Statistics for the Proposed Model, the HCC Model, and the RxRisk
Model for the Aged and the Young Disabled Adults
Proposed Model
Aged Disabled

HCC Model
Aged Disabled

RxRisk Model
Aged Disabled

Statistics
Number of Enrollees
Number of Predictors
R2
Validated R2
RMSE
Variables
Intercept

242,192 144,845 242,192 144,845 242,192 144,845
93
91
81
79
42
38
0.32
0.25
0.17
0.23
0.30
0.16
0.32
0.25
0.17
0.23
0.30
0.16
1,174.92 1,627.39 1,299.12 1,648.85 1,187.07 1,725.33
PM
PM
PM
PM
PM
PM
279.11 524.12 488.57 563.48 297.02 705.22

Female
-120.97
-47.56
106.20
371.59
703.33
1018.77
1369.69

-28.84
93.29
-55.73
-86.97
-78.26
- -62.43
3.49
- 185.48
- 516.27
- 925.70
- 1282.72
- 1617.23

- -52.54
-51.84
94.83
-1.22
-24.19
- -211.08
-40.88
- -255.85
-48.77
- -262.44
- -122.97
-67.29
79.02
- 337.02
- 657.66
- 966.27
- 1316.01
-

18–24 Years
25–34 Years
35–44 Years
45–54 Years
55–64 Years
65–69 Years
70-74 Years
75–79 Years
80-84 Years
85–89 Years
90-94 Years
95 Years or over

37.84
146.72
323.17
587.15
773.01
1006.31

237.26
84.45
0.41
31.41
26.37
- 166.63
- 410.79
- 763.69
- 986.72
- 1140.63

256.26
108.84
10.91
22.16
-

16.77
120.29
287.48
533.99
721.91
949.89

214.23
18.11
-81.90
-60.23
-

HCC variables
Infection
HCC1
HCC2
HCC5

638.05
351.37
-253.75

950.89 1132.92 1039.33
530.62 607.81 573.93
896.15 -294.49 959.37

-

-

18–24 Years
25–34 Years
35–44 Years
45–54 Years
55–64 Years
65–69 Years
70-74 Years
75–79 Years
80-84 Years
85–89 Years
90-94 Years
95 Years or over
Male
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Neoplasm
HCC7
HCC8
HCC9
HCC10
Endocrinal Disorders
HCC15
HCC16
HCC17
HCC18
HCC19
HCC21
Gastrointestinal
Disorders
HCC25
HCC26
HCC27
HCC31
HCC32
HCC33

329.59
-129.70
-131.86
-55.24
902.32
279.37
133.08
289.71
107.71
769.06

4.16
196.95
-167.63
388.66
97.81
106.28

508.65 1153.19
142.42 578.79
-4.85 128.33
66.05
-57.23

-

-

575.41
442.04
419.29
252.35
189.46
789.10

-

-

805.47 -242.31 485.16
4.62 271.74 152.08
194.06
-41.52 281.49
464.33 543.89 556.99
149.00
49.83 220.29
-92.40
45.11 -122.63

-

-

157.26
61.24

-

-

998.78
495.47
69.38
32.44

462.09 1110.82
340.70 369.90
378.67 160.75
201.77 410.25
137.68 128.65
783.46 827.42

Connective Tissue
Disease
HCC37
HCC38

94.18
-49.75

Hematological
Disorders
HCC44
HCC45

211.31 1278.71
247.85 496.35

277.28 1274.97
332.46 561.70

-

-

Psychiatric Disorders
HCC51
HCC52
HCC54
HCC55

419.61
-42.91
954.61
396.07

599.24
70.93
953.02
630.69

8.02
183.47
676.85
191.00

-

-

Spinal Cord Disorders
HCC67
HCC68
HCC69

992.65 2540.17
599.40 895.19
208.78 381.20

940.41 2619.79
595.42 936.97
182.82 422.97

-

-

47.99 1710.88
67.68 1663.91
-235.38 137.77 -129.38 313.48
1482.59 320.41 1757.72 461.24
624.72 413.82 851.10 720.18
584.43 647.71 1059.17 1070.44

-

-

Neurological
Disorders
HCC70
HCC71
HCC72
HCC73
HCC74

168.74
53.30

-11.95
121.46
440.43
-81.48
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216.08
14.59

HCC75

490.73

442.88

-

-

Respiratory Disorders
HCC77
HCC78

937.73 1489.20 1089.04 1542.30
71.88 485.02 443.41 565.26

-

-

514.08

625.18

Cardiac Diseases
HCC79
HCC80
HCC81
HCC82
HCC83
HCC92

157.94
233.49
-61.56
-112.26
-191.59
113.84

290.09
419.11
168.72
96.40
-32.76
174.39

-

-

Cerebral and
Vascular Diseases
HCC95
HCC96
HCC100
HCC101
HCC104
HCC105

-92.44
56.53
-35.43 125.95
582.30 285.71 778.67 267.36
506.01 632.72 690.24 595.09
1484.98 2167.79 1642.43 2183.22
346.45 493.64 435.06 517.01
537.08 206.29 680.87 246.66

-

-

Pulmonary Diseases
HCC107
HCC108
HCC111
HCC112

-276.54
-272.45
682.89
-82.59

152.02 1520.66
-33.77 315.80
873.28 686.64
-38.93 232.49

-

-

292.71 399.26
392.63 359.68
171.21 -143.30
81.88 -136.20
-63.69 -225.33
150.17 104.26

183.71
198.32
736.77
221.48

Eye Disorders
HCC119

-46.76

10.05

-

-

Renal Disorders
HCC130
HCC131
HCC132

507.48 1181.70 1050.71 1924.46
359.16 493.86 456.80 535.42
36.03 133.76
-96.51 130.00

-

-

Skin Disorders
HCC148
HCC149
HCC150

581.37 707.38
357.14 514.82
- -845.99

750.18 756.87
515.12 539.20
- -965.15

-

-

Injury
HCC154
HCC155
HCC157
HCC158
HCC161
HCC164

- 1153.89
- 1282.70
927.97 112.01 1238.58 116.40
198.52 277.55 346.92 314.13
334.12 221.28 560.90 186.56
130.06 122.16 247.82 152.31
321.83 209.06 474.12 246.58

-

-

Others
HCC174

348.84

494.98

-

-

-40.67 -100.50

3.11
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837.32

HCC176
HCC177

512.00 1378.58
451.30 689.39

715.73 1417.84
434.47 749.75

-

-

CDS Variables
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
A13
A14
A15
A16
A17
A18
A19
A20
A21
A22
A23
A24
A25
A26
A27
A28
A29

-17.23 299.51
326.27 128.45
134.74 116.84
-8.04 228.47
5.41
18.75
-164.73
-37.43
41.94
20.88
137.14 -167.80
-177.33 -190.27
799.74 1179.06
210.55 209.75
704.13 448.37

-

- -293.85 218.55
- 514.55 1283.73
- 631.87 1043.85
- -37.04 398.03
- 265.56 237.55
24.43
89.38
- 294.91 268.26
40.41 260.77
- 374.71 -167.51
- 191.87 290.34
- 589.68 791.41
- 120.04 246.50
- -24.09 280.22
- -57.65 108.21
-5.80
- -59.59
- -214.44 -145.51
51.87
-3.41
46.75
- 102.12
5.24 1371.01
- 254.95 826.56
- 114.67 -22.35
- -186.48 -283.17
- 648.48 349.09
- 978.58 478.58
- 919.85 2260.73
91.78
- -89.21
- 185.84 228.29
- 283.19 -101.03
- 766.87 1097.29

Notes: PM is Parameter. “-” indicates a variable that is not relevant for a particular
model.
The young disabled subpopulation of Medicaid beneficiaries consisted of
144,845 enrollees, compared with 242,192 enrollees in the aged subpopulation.
Generally, the proposed model and the RxRisk model have poorer predictive
performance in the young disabled subpopulation than in the aged subpopulation as
indicated by lower R2 value and high RMSE in the former subpopulation. The
proposed model explains 25 percent of variance in the young disabled adults’ PMPM
medical costs, compared with 32 percent in the aged population. The R2 value of the
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RxRisk model for the young disabled subpopulation is 0.16, compared with 0.30 for
the aged subpopulation. However, the HCC model has higher R2 value (R2 = 0.23) for
the young disabled subpopulation, compared with 0.17 for the aged subpopulation.
The results of statistics for the young disabled subpopulation can also be found in
Table 5.
RMSE had a higher value in all three models for the young disabled
subpopulation than the aged subpopulation. The proposed model had the lowest
RMSE (RMSE = 1,627.39) for the young disabled subpopulation among all models.
Age had a nonlinear effect on PMPM total Medicaid claims for the young
disabled subpopulation in all three models. The “25-34-year-old male” group and the
“25-34-year-old female” group had the highest PMPM medical costs among male and
female younger disabled adults respectively, and male beneficiaries had higher PMPM
medical costs than female beneficiaries.
The proposed model has better predictive performance than the HCC model
and the RxRisk model. Among all infectious diseases, AIDS is associated with the
highest increase in PMPM total Medicaid claims for both the aged and the young
disabled subpopulation. The proposed model predicts that AIDS increases the PMPM
medical cost by $638.05 in the aged subpopulation and by $950.89 in the young
disabled subpopulation.
Metastatic cancers and acute leukemia are associated with higher increase in
the PMPM total Medicaid cost for both the aged and the young disabled
subpopulation than other diseases in the “neoplasm” group. The proposed model
predicts that Metastatic cancers and acute leukemia increase the PMPM medical cost
by $638.05 in the aged subpopulation and by $950.89 in the disabled subpopulation.
Diabetes with renal or peripheral circulatory manifestation increases the
PMPM medical cost by $902.32 in the aged subpopulation, compared with $462.09 in
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the disabled subpopulation. Protein-calorie malnutrition is associated with $769.06 of
increase in the PMPM medical cost in the aged subpopulation and $783.46 of
increase in the young disabled subpopulation.
End-stage liver disease increases the PMPM medical cost by $805.47 in the
young disabled subpopulation and $4.25 in the aged subpopulation. Severe
hematological disorders are associated with $1,278.71 of increase in PMPM total
Medicaid claims for the young disabled subpopulation, and $211.31 of increase in
claims for the aged subpopulation.
Schizophrenia increases the PMPM medical cost by $954.61 in the aged
subpopulation and $440.43 in the young disabled subpopulation. Among neurological
disorders, quadriplegia and paraplegia increase PMPM medical costs by $2,540.17
and $895.19 respectively in the young disabled subpopulation, and $992.65 and
$599.40 respectively in the aged subpopulation. Muscular dystrophy increases the
PMPM medical cost by $1,710.88 in the young disabled subpopulation, and multiple
sclerosis increases the PMPM medical cost by $1,482.59 in the aged subpopulation.
Respiratory dependence is associated with high increase in PMPM total
Medicaid claims, which is $937.73 in the aged subpopulation and $1,489.20 in the
young disabled subpopulation. Among all cardiac diseases, congestive heart failure
increase the PMPM medical cost by the largest margin, which is $233.49 in the aged
subpopulation and $392.63 in the young disabled subpopulation.
Cerebral palsy and other paralytic syndromes increase the PMPM medical cost
by $1,484.98 in the aged subpopulation and $2,167.79 in the young disabled
subpopulation. Dialysis increases the PMPM medical cost by $1,181.70 in the young
disabled subpopulation, and a major head injury increases the PMPM medical cost
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Table 6: Predictive Ratios in the HCC model and Proposed Model for the Aged
Subpopulation
Diseases
Acute Myocardial Infarction
Aspiration and Specified Bacterial Pneumonias
Cardio – Respiratory Failure and Shock
Chronic Obstructive Pulmonary Disease
Congestive Heart Failure
Diabetes with Renal or Peripheral Circulatory
Manifestation
Dialysis Status
End-Stage Liver Disease
Hip Fracture/Dislocation
Inflammatory Bowel Disease
Ischemic or Unspecified Stroke
Major Depressive, Bipolar, and Paranoid Disorders
Metastatic Cancer and Acute Leukemia
Parkinson’s and Huntington’s Disease
Renal Failure
Schizophrenia
Note: PR means predictive ratio.

Proposed Model
PR
1.02
0.97
0.93
0.99
0.97

HCC Model
PR
0.91
0.95
0.84
0.99
0.93

0.99
1.00
0.78
1.00
0.99
0.96
0.98
0.78
0.97
0.99
0.90

0.94
0.99
0.74
1.00
0.99
0.96
0.98
0.78
0.95
0.97
0.90

by $927.97 in the aged subpopulation.
Model performance can also be evaluated by the predictive ratio. The
predictive ratio is calculated by dividing predicted medical cost by actual medical cost
in the year 2 data within different subgroups. The ideal value of predictive ratio is 1,
which means the mean of predicted medical cost is equal to the mean of actual
medical cost. Risk-adjustment models with predictive ratios closer to 1 are regarded
as the models with higher predictive power. In Table 6, predictive ratios in the HCC
model and the proposed model for the aged subpopulation are listed. The results
show that the proposed model has better predictive ratios than the HCC model in all
disease groups except chronic obstructive pulmonary disease, hip fracture,
inflammatory bowel Disease, ischemic or unspecified stroke, major depression,
metastatic cancers and schizophrenia.
The aged subpopulation and the young disabled subpopulation account for
different proportion among all Florida Medicaid beneficiaries. In SFY 2002-03, 10.5
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percent of Medicaid enrollees were aged 65 or above and 6.27 percent of Medicaid
enrollees were disabled adults younger than 65. The distribution of SFY 2002-03
PMPM medical costs among two subpopulations of Medicaid enrollees is listed in
Table 7. Except for the 90th percentile, the young disabled subpopulation has higher
PMPM medical costs in all percentiles listed in Table 7. Figure 2 draws the picture of
distribution of SFY 2002-03 PMPM medical costs in percentiles among two
subpopulations. The blue triangle sign indicates the number of the younger disabled
beneficiaries’ PMPM costs in each percentile strata and the red dot sign indicates the
number of the aged beneficiaries’ PMPM costs in each percentile strata. The younger
disabled beneficiaries, whose PMPM costs fall within top 5 percentiles, need much
more reimbursements than their counterparts in the aged subpopulation.
The average PMPM costs in various disease groups are also different for the
aged subpopulation and the young disabled subpopulation, as shown in Figure 1.
Among the patients with psychotic diseases, younger disabled Medicaid enrollees
have higher PMPM costs than older enrollees. The younger patients with renal or
pulmonary diseases including renal failure and pneumonia also need much more
reimbursement for their health care services than their older counterparts. However,
the younger patients with chronic heart failure have similar medical costs with their
older counterparts. Acute myocardial infarction is associated with higher PMPM
medical cost in the young disabled subpopulation than in the aged subpopulation.
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Table 7: Distribution of SFY 2002-03 PMPM Medical Costs among Two Subpopulations
of Medicaid Enrollees
Percentile
Maximum
99
95
90
75
50
25
10
5
1

Aged
34838.30
5218.20
4322.18
3618.42
921.56
311.88
90.91
0.00
0.00
0.00

Disabled
68970.28
9092.51
4877.27
2702.80
1025.14
526.97
260.34
61.08
5.54
0.00

Schizophrenia
RF
Leukemia
Depression
Stroke
IBD
Younger Disabled
Aged

Dialysis
Diabetes
CHF
COPD
Shock
Pneumonia
Acute MI
0

1000

2000

3000

4000

5000

Figure 1: The Average PMPM Costs in Various Disease Groups for Two
Subpopulations
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Figure 2: Distribution of SFY 2002-03 PMPM Medical Costs in Percentiles among Two
Subpopulations
Note: RF is renal failure. IBD is inflammatory bowel disease. CHF is chronic heart
failure. COPD is chronic obstructive pulmonary disease. MI is myocardial infarction.
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Chapter Four
Discussion
Capitation payment systems based on risk adjustment methodologies can
more equitably reimburse health plans with a large proportion of sicker beneficiaries
if an effective risk adjustment model with high predictive power is developed. In
former studies exploring risk adjustment methodologies, diagnoses and prescription
drug usage respectively were used to build predictive models. In this dissertation, a
model using information about diagnoses and prescription drug usage was built and
compared with diagnosis-based and pharmacy-based models.
Since Medicaid beneficiaries other than the aged and the young disabled
account for a large proportion (83.2 percent), it is necessary to compare the models
for the aged and the young disabled subpopulations with the models based on the
whole Medicaid population. The results show that the proposed model and the
pharmacy-based RxRisk model predict the aged beneficiaries’ PMPM medical costs
better than they do for the whole Florida Medicaid population’s PMPM costs. The
variance explained for the aged beneficiaries subpopulation using the proposed
model is slightly greater than that explained by the RxRisk model. The HCC model,
however, predicts the general Florida Medicaid population’s PMPM costs better than it
does for the aged beneficiaries’ costs. All models run against the aged subpopulation
have higher RMSE and are therefore less accurate than the same models run against
the general Medicaid population. The pharmacy-based RxRisk model had very close
predictive performance in contrast to the proposed model for the aged subpopulation
and it can be a good replacement for the HCC model because of its excellence in
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predictive performance and practical implementation.
The proposed model has better or equal predictive ratios than the HCC model
currently applied in Medicare capitation payment system, for those disease groups
examined in this dissertation. Predictive ratio is an important factor used to evaluate
risk adjustment model performance. Predicted PMPM costs in the proposed model are
closer to the observed costs in the aged Medicaid subpopulation than predicted costs
using the HCC model. The proposed model also has better performance and accuracy
than the HCC model for Florida Medicaid capitation payment system.
The same disease can be associated with differential increases in PMPM costs
in the aged and the young disabled subpopulations. The disease groups falling within
different levels of increased costs in both subpopulations are listed in Table 8. The
increases of PMPM costs for different diseases in the aged and the young disabled
subpopulations are divided into five levels: less than $0, $0 to $400, $400 to $700,
$700 to $1,000, more than $1,000. Some HCC categories had negative cost
increments and these appear in the category <0.
Within the “more than $1,000 increase” category, two diseases can be found
for the aged subpopulation and eight diseases for the young disabled subpopulation.
For the aged subpopulation, two neurological diseases fell in the category with the
highest PMPM cost increase: cerebral palsy and multiple sclerosis. Cerebral palsy is
also associated with the second highest PMPM cost increase in the young disabled
subpopulation. There is a large gap between younger and older patients’ medical
costs for multiple sclerosis. Multiple sclerosis increases the PMPM cost by more than
$1,000 for the older patients, but falls within the “$0-$400 increase” in the young
disabled adults. Multiple sclerosis is costly because it has a major lifetime impact
(Whetten-Goldstein et al., 1998). The costs for personal assistant and prescription
drugs are major expenses for multiple sclerosis (Henriksson et al., 2001) and older
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patients may incur more medical expenditures since they have increased disability
and more frequent relapse.
Several diseases fell within the “more than $1,000 increase” level for the
young disabled subpopulation. Of these diseases, several can be found in the “$700$1000 increase” level for the aged subpopulation: quadriplegia, head injury, and
respirator dependence. It is likely that medical care for muscle weakness would be
associated with high medical costs in both subpopulations since all five diseases
mentioned above can lead to respiratory weakness and weakness in other body
systems. Muscular dystrophies consist of genetic disorders characterized by progressive
muscle wasting and weakness and fell within the “more than $1,000 increase” level for

the young disabled subpopulation and the “$0-$400 increase” level for the aged
subpopulation. A possible explanation for this finding is that muscular dystrophies can
be very severe and affect the respiratory system if they begin in childhood. Older
patients with muscular dystrophies have been found to have less severe symptoms
and need less medical attention than their younger counterparts. Three medical
conditions are associated with more than $1,000 increase in PMPM medical cost for
the young disabled subpopulation but less than $700 for the aged subpopulation:
artificial openings for feeding or elimination, severe hematological disorders, and
dialysis status. Patients with these conditions usually need continuous transfusion of
blood or feeding devices, which can be costly. The results indicate that younger
disabled Medicaid enrollees need more medical care in transfusion and feeding.
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Table 8: Disease Groups in Different PMPM Cost Increase Categories for the Aged
and the Young Disabled Subpopulation

PMPM Cost Increase
Categories
>1,000

Aged

Younger Disabled

Cerebral Palsy

Quadriplegia

Multiple Sclerosis

Cerebral Palsy
Muscular Dystrophy
Respirator Dependence
Artificial Openings for
Feeding or Elimination
Severe Hematological
Disorders
Dialysis Status
Severe Head Injury

700-1000

Quadriplegia
Schizophrenia
Respirator Dependence
Major Head Injury

Metastatic Cancer and
Acute Leukemia
HIV/AIDS
Opportunistic Infections
Paraplegia

Diabetes with Renal or
Peripheral Circulatory
Manifestation
Protein-Calorie
Malnutrition

End-Stage Liver Disease
Protein-Calorie
Malnutrition
Aspiration and Specified
Bacterial Pneumonias
Decubitus Ulcer of Skin
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400-700

Aspiration and Specified
Bacterial Pneumonias

Amputation Status

HIV/AIDS
Parkinson’s and
Huntington’s Diseases
Paraplegia
Seizure Disorders
Ischemic Stroke
Decubitus Ulcer of Skin
Vascular Disease

Seizure Disorders and
Convulsions
Hemiplegia
Septicemia/Shock
Chronic Ulcer of Skin
Coma
Disorders of Immunity

Artificial Openings for
Feeding or Elimination

Lung, Upper Digestive
Tract, and Other Severe
Cancers

Dialysis Status

Renal Failure

Hemiplegia

Vascular Disease with
Complications

Coma
Amputation Status
Drug/Alcohol Psychosis

Respiratory Arrest
Intestinal
Obstruction/Perforation
Diabetes with Renal or
Peripheral Circulatory
Manifestation
Schizophrenia
Parkinson’s and
Huntington’s Diseases
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0-400

Major Depressive,
Bipolar, and Paranoid
Disorders
Intestinal Obstruction
Renal Failure
Chronic Ulcer of Skin
Septicemia/Shock
Major Organ Transplant
Status
Vascular Disease with
Complications
Hip Fracture
Metastatic Cancer and
Acute Leukemia
Major Complications of
Medical Care and
Trauma
Diabetes with
Ophthalmologic or
Unspecified
Manifestation
Diabetes with Neurologic
or Other Specified
Manifestation
Disorders of Immunity
Congestive Heart Failure
Severe Hematological
Disorders
Spinal Cord
Disorders/Injuries
Vertebral Fractures
without Spinal Cord
Injury
Cirrhosis of Liver
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Congestive Heart Failure
Spinal Cord
Disorders/Injuries
Diabetes with Acute
Complications
Diabetes with Neurologic
or Other Specified
Manifestation
Multiple Sclerosis
Cardio-Respiratory
Failure and Shock
Ischemic Stroke
Vertebral Fractures
without Spinal Cord
Injury
Pneumococcal
Pneumonia
Hip Fracture/Dislocation
Major Complications of
Medical Care and
Trauma
Vascular Disease
Diabetes with
Ophthalmologic or
Unspecified
Manifestation
Chronic Obstructive
Pulmonary Disease
Chronic Hepatitis
Cystic Fibrosis
Acute Myocardial
Infarction
Bone/Joint/Muscle
Infections/Necrosis

0-400

Cardio-Respiratory
Failure and Shock

Specified Heart
Arrhythmias

Diabetes with Acute
Complications

Pancreatic Disease
Polyneuropathy

Traumatic Amputation
Specified Heart
Arrhythmias
Inflammatory Bowel
Disease
Pancreatic Disease

Diabetes without
Complication
Nephritis
Traumatic Amputation
Drug/Alcohol
Dependence
Major Head Injury

Bone/Joint/Muscle
Infections/Necrosis
Respiratory Arrest
Cerebral Hemorrhage
Muscular Dystrophy
Nephritis
End-Stage Liver Disease

Unstable Angina and
Other Acute Ischemic
Heart Disease
Lymphatic, Head and
Neck, Brain, and Other
Major Cancers
Rheumatoid Arthritis
and Inflammatory
Connective Tissue
Disease
Breast, Prostate,
Colorectal and Other
Cancers and Tumors
Cirrhosis of Liver
Major Organ Transplant
Status
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<0

Drug or Alcohol
Dependence
Proliferative Diabetic
Retinopathy and
Vitreous Hemorrhage
Rheumatoid Arthritis
and Inflammatory
Connective Tissue
Disease
Breast, Prostate,
Colorectal and Other
Cancers and Tumors
Acute Myocardial
Infarction
Pneumococcal
Pneumonia

Drug/Alcohol Psychosis
Cerebral Hemorrhage
Proliferative Diabetic
Retinopathy and
Vitreous Hemorrhage
Angina Pectoris/Old
Myocardial Infarction
Major Depressive,
Bipolar, and Paranoid
Disorders
Inflammatory Bowel
Disease
Extensive Third-Degree
Burns

Unstable Angina and
Other Acute Ischemic
Heart Disease
Lung, Upper Digestive
Tract, and Other Severe
Cancers
Lymphatic, Head and
Neck, Brain, and Other
Major Cancers
Chronic Hepatitis
Angina Pectoris/Old
Myocardial Infarction
Polyneuropathy
Opportunistic Infections
Chronic Obstructive
Pulmonary Disease
Cystic Fibrosis
Note: Diseases in each PMPM cost categories are ranked by amount of costs.
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Diseases in the “$700-$1000 increase” level are mostly of an infectious
nature for the young disabled subpopulation. Four diseases in this level are directly
related to opportunistic infections: HIV/AIDS, opportunistic infections, pneumonias,
and decubitus ulcer of skin. Some diseases in this category have indirect association
with infections. For example, patients with acute leukemia may have low numbers of
white cells and their risk for opportunistic infections increases dramatically. Endstage liver disease and protein-calorie malnutrition lead to low protein levels and a
decline in the blood antibody level coincident with a fall in the body protein level.
Opportunistic infections do not increase the medical cost, as predicted by the
proposed model. The results indicate that medical care for infections cost less in
older ages.
For the aged subpopulation, most diseases in the “$700-1000 increase
category” are neurological disorders. Schizophrenia, which is a type of mental
disorder, is also associated with high medical costs. In the young disabled
subpopulation, it falls within the “$400-$700” categories.
Most diseases are associated with higher predicted PMPM medical costs in the
young disabled subpopulation than in the aged subpopulation. This finding may be
due to the fact that younger patients suffer more severe medical conditions than
older patients who have the same diseases. For example, younger patients need
higher doses of prescription drugs than older patients because they more rapidly
metabolize medications. Moreover, Medicaid pays for almost all medical costs for
younger disabled adults, but it only reimburses the costs of prescription drugs for the
aged subpopulation since older Medicaid beneficiaries are likely to be eligible for
Medicare and Medicare reimburses many health care services. Hence, PMPM costs of
the older Medicaid beneficiaries are likely to be underpredicted since Medicaid claims
do not include all medical expenditures.
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Diseases associated with high PMPM costs merit further attention from health
care providers and investigators. These diseases place a heavy financial burden on
the Medicaid capitation payment system. Health care providers who find cost-saving
methods to manage patients with these diseases will reap significant financial
returns.
The proposed model represents an improvement of 15% in variance
accounted for over the current HCC model for the Medicaid capitation system for the
aged subpopulation, since the proposed model R2 was 0.32 while the HCC model was
0.17. However, several changes can be made which may yield further improvements
in the proposed model. The proposed model has a larger RMSE value for the aged
and the young disabled subpopulations than the general Medicaid population, which
may indicate that additional predictors associated with medical costs can be added
into the proposed model to improve performance. Some pharmacy-based adjusters
were not included in the proposed model because of potential interactions among the
current set of predictors, however a possible solution is the statistical transformation
of these adjusters. Moreover, current RxRisk adjusters were developed for chronic
conditions only; new RxRisk adjusters for acute conditions should be developed to
increase the predictive accuracy of models with pharmacy-based adjusters. The
procedure codes reported in Medicaid claims may contribute unique variance to the
proposed model and significantly affect the prediction of medical costs.
In this dissertation, R-square value and RMSE were used to evaluate the
predictive power of risk adjustment models, and they are both statistical indicators
of the overall predictive performance of risk adjustment models. For example, a risk
adjustment model with high R-square value and low RMSE can predict more variance
of medical expenditures in the next year than models having lower R-square values
and higher RMSE. The predictive ratio was used to estimate the power of models
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using individual risk adjusters and the proposed model had a better predictive ratio
than the HCC model for the aged subpopulation. However, both models had weak
predictive performance for some risk adjusters including end-stage liver disease and
metastatic cancer. In future research some improvements can be made to the
proposed model. There were two types of health status predictors in the proposed
model: diagnosis-based HCC adjusters and pharmacy-based RxRisk adjusters. Each
HCC adjuster represented a group of diseases associated with similar clinical
characteristics and costs. The distribution of each HCC disease group should be
examined to find extremely high or low values (outliers). The results show that the
proposed model poorly predict the costs of some disease groups, such as end-stage
liver disease and metastatic cancer and a large number of outliers may play a role in
poor predictive performance of the proposed model for end-stage liver diseases and
metastatic cancers (Edwards et al., 2000). For example, patients with extremely high
medical costs within a disease group can make the average cost of this disease
group increase sharply and risk adjustment models will probably overpredict medical
costs for other patients in this group. Two possible solutions are the removal of these
extreme values and the addition of new variables as substitutes for these extreme
values. The removal of extreme values can decrease variance within a disease group.
The addition of new variables can divide medical costs for a disease group into two
groups: extreme values and non-extreme values so researchers can estimate
average medical costs for both groups, add them into risk adjustment models
respectively, and address the need of patients with both extreme and non-extreme
values. Predictive ratio is an important indicator for evaluation of predictive
performance of models for individual risk adjusters, and both solutions mentioned in
the early context should be attempted to make the predictive ratio as close to 1 as is
possible.
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Second, adding more variables improves the predictive performance of risk
adjustment models. Risk adjusters based on durable medical equipment (DME), may
be a new class of health condition variables. The definition of DME varies across state
Medicaid systems which have set different standards for DME (www.nls.org).
Generally, equipment must meet four criteria to be considered DME: (1) it can be
used repeatedly over extended intervals; (2) it is serves a medical purpose; (3) it is
functionally useless to persons not having the illness or injury which it was designed
to ameliorate; (4) it is appropriate for usage at home. These four criteria are the
only criteria for DME in Florida but different criteria are found for other states. For
example, the Georgia Medicaid system requires that DME also must have a warranty.
The Connecticut Medicaid system requires that DME also must be non-disposable.
The criteria for DME can be found in state Medicaid manuals in different states. DME
can provide more information on patients’ health conditions that may be not
accounted for by diagnosis or pharmaceutical adjusters. For example, wheelchair is a
DME in Florida. Patients who are in need of wheelchairs may have worse health
condition than patients without walking difficulties. Hence, patients using wheelchairs
may incur higher medical costs than their counterparts without walking difficulties.
However, all these patients are assumed to have same medical costs under risk
adjustment models without wheelchair variables. In future research using this model,
all DME will be reviewed and DME that have effects on future medical costs will be
added into the proposed model to attempt to increase predictive power.
Future research will concentrate on improving risk adjustment models and the
application of improved risk adjustment models in the Florida Medicaid capitation
payment system. Improvement of risk adjustment models involves empirical reviews
of statistical methods and clinical practice. An ideal risk adjustment model must have
strong predictive power and easy implementation in clinical practice. As mentioned
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earlier, the addition of new variables and removal of outliers may increase predictive
accuracy of the proposed model. However, the proposed model’s practical
implementation must be addressed. The collection of diagnosis-based and pharmacybased data may be time-consuming for health plans since both diagnoses and
prescription drug records must be obtained and used to calculate predicted medical
costs. Capitation systems based on the proposed model may meet resistance from
health plans because of the increased workload imposed by this method. Possible
solutions include the simplification of data-reporting processes for health plans and
innovations in computer software that can handle more complicated medical costs
calculations. Capitation payment systems based on the proposed model will have
several advantages: (1) the proposed model can predict medical costs more
accurately. The proposed model has more risk adjusters than the HCC model and the
RxRisk model, and the results in this dissertation have shown that it had more
predictive power statistically than the competing models. Predicted medical costs
based on the proposed model will be closer to actual medical costs than medical
costs predicted by other models; (2) the proposed model can decrease the possibility
of gaming since it utilizes both diagnostic and pharmaceutical information to predict
future medical costs. Prescription drug usage can provide more information on
patients’ health conditions that cannot be inferred from diagnoses. Hence, patients’
health condition will be more easily identified using the proposed model compared
with the HCC model. Health plans will have fewer opportunities to game the
capitation payment system.
The RxRisk model is approximately equal to the proposed model in predictive
accuracy for the aged Medicaid subpopulation. It has advantages in practical
implementation, such as less work of collecting data and high reliability of data.
However, it is suggested as a strategy for the aged enrollees only since the
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predictive accuracy of the RxRisk model for the young disabled subpopulation was
significantly lower than the proposed model in this study.
The proposed model is recommended to be the risk adjustment model for the
Florida Medicaid capitation payment system because it has been shown to
outperform competing alternatives. Generally, the proposed model outperformed
current risk adjustment models in capitation payment systems. As national health
expenditures keep rising in the near future, improvement of capitation payment
systems based on risk adjustment methodology is necessary, and this dissertation
proposes a better model than current ones. It can be implemented in the Florida
Medicaid capitation payment system to improve predictive accuracy and save
medical expenditures.
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